Serina Therapeutics to Present at BTIG Virtual Biotech Conference
Event summary
- Serina Therapeutics will participate in the BTIG Virtual Biotechnology Conference on July 28-29, 2026.
- Management will hold virtual one-on-one investor meetings on July 29, 2026.
- Serina’s POZ Platform™ technology aims to optimize drug delivery for neurological diseases and other indications.
- SER-252 (POZ-apomorphine) is designed to reduce levodopa-related motor complications in Parkinson’s disease.
The big picture
Serina Therapeutics is positioning itself as a key player in drug optimization technology, leveraging its POZ Platform™ to enhance the efficacy and safety of existing therapies. The company’s participation in the BTIG Virtual Biotechnology Conference underscores its focus on engaging with investors and advancing its pipeline of neurological disease treatments. With partnerships like Pfizer, Serina aims to broaden the applicability of its technology across various therapeutic areas.
What we're watching
- Partnership Dynamics
- How Serina’s collaboration with Pfizer on lipid nanoparticle drug delivery formulations will progress.
- Clinical Development
- The pace at which SER-252 advances through clinical trials and regulatory approvals.
- Market Positioning
- Whether Serina can differentiate its POZ Platform™ in a competitive biotech landscape.
Related topics